• Alisa Serio, Executive Director of Microbiology and Nonclinical Development, Paratek Pharmaceuticals (USA)
  • Victoria Savage, Chief Scientific Officer, INFEX Therapeutics Ltd (UK)


  • Daniel Ritz, Senior Director – Senior Group Leader Biology Technologies / Lead Discovery, Idorsia Pharmaceuticals Ltd. (Switzerland)

This webinar will focus on the particular challenges regarding progressing antibacterial drug discovery projects for small and medium-sized enterprises (SMEs) and their potential solutions.

Presentation 1: Progression criteria and go/no go decisions in antibacterial drug discovery – a perspective from Paratek Pharma (Alisa Serio)

  • Overview of the drug discovery process through approval & commercialization
  • Strategic considerations for each phase of an antibacterial program
  • How non-dilutive funding can play a key role in SME programs
  • Examples of go/no-go decisions

Presentation 2: Progressing an antibacterial drug discovery program – a perspective from INFEX Therapeutics (Victoria Savage)

  • Introduction to the role of SMEs in antibacterial drug development
  • Where SMEs fit in the development pipeline
  • Challenges for SMEs
  • Case studies for successful and unsuccessful programs

This live webinar including an interactive Q&A session will be broadcast on 27 June 2024 at 17:00 – 18:30 CEST. Find your timezone here.

If you have questions or comments, please let us know: revive@gardp.org.